Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...

“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD. Daraxonrasib reduced the risk of death by 60% compared with ...

Discusses Clinical Data and Updated Development Strategy for Darlifarnib June 3, 2026 3:15 PM EDTCompany ParticipantsTroy ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Getting the most out of A/B and other controlled tests by Ron Kohavi and Stefan Thomke In 2012 a Microsoft employee working on Bing had an idea about changing the way the search engine displayed ad ...

Rare cardiovascular diseases affect 5% of the world’s population. Rare disease training for clinicians is essential to suspect and diagnose underlying rare diseases and to work effectively with ...

"Early molecular testing is critically important now in these mCSPC patients,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD. Adding talazoparib to enzalutamide reduced the risk of radiographic ...